Medicus Pharma Ltd. 8-K

What Happened
Medicus Pharma Ltd. announced on Form 8-K (filed April 24, 2026) that it amended its Equity Distribution Agreement on April 23, 2026 to increase its "at-the-market" (ATM) offering capacity from $15,349,674 to up to $50,000,000. The company has raised approximately $11.5 million so far under the ATM program. Separately, on April 21, 2026 the company received a Nasdaq notice that its closing bid price had been below $1.00 for the prior 30 consecutive business days, triggering noncompliance with Nasdaq Listing Rule 5550(a)(2).

Key Details

• ATM upsize: aggregate offering amount increased to up to $50,000,000 (Amendment No. 1 dated April 23, 2026).
• Amount raised to date: ~ $11.5 million sold under the ATM program.
• Agents: Maxim Group LLC and Yorkville Securities, LLC remain sales agents under the agreement.
• Nasdaq noncompliance: Notice received April 21, 2026; company has 180 calendar days (until October 19, 2026) to regain a $1.00+ closing bid for 10 consecutive business days. A second 180-day period may be available if certain conditions are met.
• The Nasdaq notice does not affect listing or trading immediately; the company may appeal a delisting determination later if one is issued.

Why It Matters
The ATM upsize gives Medicus Pharma greater capacity to raise cash by selling common shares into the market, which can provide funding flexibility but may dilute existing shareholders and increase share supply. The Nasdaq notice signals a risk to continued Nasdaq Capital Market listing if the company’s stock price does not recover to at least $1.00 per share for the required period. Both items are material for investors because they affect financing options, potential dilution, and the trading status and liquidity of the stock.